Approval of Clinical Trial Application for Phase I study of Medherant’s testosterone patch for post-menopausal women
The study will be conducted by Hammersmith Medicines Research (HMR; London) and enrol up to 24 women to investigate the safety, tolerability and pharmacokinetics of testosterone delivered from Medherant TEPI Patch when applied to the skin.
“Approval of this Clinical Trial Application is an important milestone in progressing the development of our testosterone patch and we look forward to working with the team at HMR on this study,” says John Burt, Medherant CEO.
About Medherant
Medherant’s lead development product is a testosterone patch for post-menopausal women utilising Medherant’s novel transdermal TEPI Patch proprietary technology. Despite the recommendation contained in the NICE Menopause Guidelines and Global Consensus Position Statement on the Use of Testosterone Therapy for Women there is no approved testosterone product for women.
The company was founded by University of Warwick’s Professor of Polymer Chemistry, Professor David Haddleton and is developing the novel transdermal TEPI Patch technology which can create patches that have more favourable wear characteristics for patients, with good adhesion and are non-irritant to patients whilst not leaving adhesive residue on patients’ skin.
In addition to developing its own products, Medherant collaborates with pharmaceutical companies in developing transdermal patch products for already approved drugs.
TEPI Patch is a registered trademark of Medherant Limited.